PharmaShots | Incisive News in 3 Shots

Subscribe Now

Oncoinvent

Oncoinvent Reports the First Patient Dosing with Radspherin in its P-II Clinical Evaluation for Ovarian Cancer

Oncoinvent Reports the First Patient Dosing with Radspherin in its P-II Clinical Evaluation for Ovarian Cancer

October 10, 2024

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us